LOS ANGELES–(BUSINESS WIRE)—- $CDXC #CellularHealth–ChromaDex Corp. (Nasdaq:CDXC) today reported third quarter financial results. 2020 Third Quarter and Recent Highlights Total net sales of $14.2 million, up 18% from $12.1 million from the year ago quarter. Tru Niagen® net sales of $11.9 million, a 22% increase from the year ago quarter. Net loss was ($4.2) million or ($0.07) per share, an improvement of $0.05 per share year-over-year. Adjusted EBITDA excluding total legal expense, a non-GAAP measure, was a loss of
News Ticker
- [ September 28, 2023 ] TAE Life Sciences Celebrates Collaboration Milestones and Unveils Alphabeam for in-hospital BNCT at ASTRO 2023 Annual Meeting Los Angeles Biotech News
- [ September 28, 2023 ] Alfred Mann Foundation Rebrands as huMannity Medtec, Unveiling a Bold, Future-Focused Identity Los Angeles Biotech News
- [ September 28, 2023 ] Medical Laboratory Scientist – VIR Healthway – Santa Monica, CA Los Angeles Biotech Jobs
- [ September 28, 2023 ] New Neoadjuvant Trial Confirms the Predictive Utility of MammaPrint® + BluePrint® Los Angeles Biotech News
- [ September 28, 2023 ] Immunis Welcomes UC Berkeley Professor Irina Conboy to the Scientific Advisory Board Los Angeles Biotech News
Copyright © 2023 Biotech Networks, LLC
